FDA Official Expects Tightened Vaccine Review

5 Key Takeaways

• 1

  Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, highlights potential changes in vaccine development under the new administration.

• 2

  Concerns arise over increased scrutiny and changes in vaccine messaging.

• 3

  Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services raises fears of regulatory changes.

• 4

  Industry insiders worry about potential impact on the FDA and vaccine makers.

• 5

  FDA workforce concerns, transparency in vaccine development, and leadership changes are key points.